GRAIL (NASDAQ:GRAL) Shares Gap Up – Should You Buy?

GRAIL, Inc. (NASDAQ:GRAL)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $80.77, but opened at $93.74. GRAIL shares last traded at $102.00, with a volume of 601,651 shares trading hands.

Analyst Ratings Changes

Several brokerages have recently issued reports on GRAL. Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a research report on Sunday, September 13th. UBS Group set a $84.00 price target on shares of GRAIL in a research report on Thursday. Wolfe Research started coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Mizuho lifted their price objective on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Finally, Royal Bank Of Canada started coverage on GRAIL in a research note on Thursday. They set a “sector perform” rating and a $84.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $70.30.

GRAIL Stock Performance

The firm’s 50-day moving average price is $74.12 and its two-hundred day moving average price is $63.54. The stock has a market cap of $4.74 billion, a price-to-earnings ratio of -10.85 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. As a group, sell-side analysts expect that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Insider Buying and Selling at GRAIL

In related news, CEO Joshua J. Ofman sold 5,000 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $85.02, for a total transaction of $425,100.00. Following the completion of the transaction, the chief executive officer owned 397,271 shares in the company, valued at approximately $33,775,980.42. The trade was a 1.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 7,900 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $85.01, for a total value of $671,579.00. Following the transaction, the chief financial officer directly owned 253,083 shares of the company’s stock, valued at approximately $21,514,585.83. This represents a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.83% of the company’s stock.

Hedge Funds Weigh In On GRAIL

A number of institutional investors have recently modified their holdings of GRAL. Caitong International Asset Management Co. Ltd acquired a new stake in shares of GRAIL in the 4th quarter worth $28,000. Fifth Third Bancorp lifted its position in GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares during the period. Allworth Financial LP acquired a new stake in GRAIL in the second quarter valued at about $35,000. Geneos Wealth Management Inc. boosted its holdings in GRAIL by 160.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after purchasing an additional 360 shares in the last quarter. Finally, Osbon Capital Management LLC purchased a new stake in GRAIL in the 4th quarter valued at approximately $51,000.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.